Business model

A business model built for the future

We are full life cycle investors creating value and offering support at any stage, from academic programs all the way to mature publicly traded companies.

What we need to create value

Experienced team

A collaborative team of doctors, academics, and drug developers coupled with seasoned venture capitalists, investment bankers, lawyers and operators with a strong compliance culture.

Scientific rigor

Our research process combines wide data-gathering with deep analysis to identify the most compelling assets, technologies, and modalities with the best chance of reaching patients.

Full lifecycle investing

Taking a long-term, full-lifecycle approach and having a true evergreen structure helps us avoid the structural constraints of venture-only or public-only vehicles.

Global reach

Great science takes place everywhere in the world. Our global reach helps us find and support innovation wherever it exists.

How we create value

Our purpose drives everything we do

Identify transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by our deep scientific understanding and a long-term approach to supporting innovative businesses, we invest in companies developing next-generation therapies and technologies that can significantly improve patients’ lives.

Identify unmet needs, Invest in relationships, Support through the life cycle

Our purpose

We power breakthrough therapies that transform the lives of millions

Broad Value Creation

Patient Benefits


RTW’s top 10 most successful investments since inception have commercialized 11 drugs

Portfolio Companies


Number of private investments that have had a liquidity event out of 61 total

Local Communities


Number of community organizations and research partners the RTW Charitable Foundation supported in responding to COVID needs in New York City

Ultrarare Disease


Rare disease research organizations supported through RTWCF grants across six countries

RTW senior team

Roderick Wong, MD

Roderick Wong, MD

Managing Partner, Chief Investment Officer
Sabera Loughran

Sabera Loughran

Partner Emeritus, Founding COO and CFO
Naveen Yalamanchi, MD

Naveen Yalamanchi, MD

Partner, Portfolio Manager
Stephanie A. Sirota

Stephanie A. Sirota

Partner, Chief Business Officer
Peter Fong, PhD

Peter Fong, PhD

Partner, President
Gotham Makker, MD

Gotham Makker, MD

Partner, Head of Strategic Investments
Robert Aurigema

Robert Aurigema

Partner, Chief Operating Officer and Chief Financial Officer
Chris Seiter

Chris Seiter

Chief Corporate Finance Officer